{"id":350857,"date":"2025-12-17T10:12:16","date_gmt":"2025-12-17T10:12:16","guid":{"rendered":"https:\/\/www.newsbeep.com\/ca\/350857\/"},"modified":"2025-12-17T10:12:16","modified_gmt":"2025-12-17T10:12:16","slug":"eli-lilly-drug-retatrutide-clinical-trial-results","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/ca\/350857\/","title":{"rendered":"Eli Lilly Drug Retatrutide Clinical Trial Results"},"content":{"rendered":"<p>Eli Lilly just announced phase 3 clinical trial results for its new medication, retatrutide, and it could become the most effective weight loss medication yet.Retatrutide is a triple-agonist medication, meaning it activates three hormone receptors involved in appetite and metabolism: GLP-1, GIP, and the glucagon receptor.While exciting, doctors stress that there are still side effects to consider, more research is needed, and this medication is not yet FDA-approved.  <\/p>\n<p data-journey-content=\"true\" data-node-id=\"2\" class=\"css-6wxqfj emevuu60\">People who don\u2019t get the <a href=\"https:\/\/www.womenshealthmag.com\/weight-loss\/\" target=\"_blank\" data-vars-ga-outbound-link=\"https:\/\/www.womenshealthmag.com\/weight-loss\/\" data-vars-ga-ux-element=\"Hyperlink\" data-vars-ga-call-to-action=\"weight loss\" data-node-id=\"2.1\" class=\"body-link css-7bauu1 emevuu60\" rel=\"nofollow noopener\">weight loss<\/a> results they\u2019re after on a <a href=\"https:\/\/www.womenshealthmag.com\/weight-loss\/a69314891\/weight-loss-drugs-lower-costs\/\" target=\"_blank\" data-vars-ga-outbound-link=\"https:\/\/www.womenshealthmag.com\/weight-loss\/a69314891\/weight-loss-drugs-lower-costs\/\" data-vars-ga-ux-element=\"Hyperlink\" data-vars-ga-call-to-action=\"GLP-1 medication\" data-node-id=\"2.3\" class=\"body-link css-7bauu1 emevuu60\" rel=\"nofollow noopener\">GLP-1 medication<\/a> like Wegovy (semaglutide) may switch to a dual-agonist drug like Zepbound (tirzepatide) under the guidance of their doctor. And because the latter medication works on two different receptors in the body, it may lead to greater weight loss. Well, there\u2019s now a triple-agonist medication waiting in the wings, and its clinical trial results are pretty impressive. <\/p>\n<p data-journey-content=\"true\" data-node-id=\"3\" class=\"css-6wxqfj emevuu60\">Eli Lilly, which makes Zepbound and Mounjaro, just announced phase 3 clinical trial results for its new medication, retatrutide, and it could become the most effective weight loss medication. <\/p>\n<p data-journey-content=\"true\" data-node-id=\"4\" class=\"css-6wxqfj emevuu60\">This medication is not yet FDA-approved, but retatrutide is already getting a ton of buzz. So, what\u2019s the deal and how is it different from what\u2019s currently available? Weight loss physicians explain. <\/p>\n<p data-journey-content=\"true\" data-node-id=\"6\" class=\"body-tip css-mtq1aa emevuu60\">Meet the experts: <a href=\"https:\/\/www.memorialcare.org\/providers\/mir-b-ali\" target=\"_blank\" data-vars-ga-ux-element=\"Hyperlink\" data-node-id=\"6.2\" data-vars-ga-outbound-link=\"https:\/\/www.memorialcare.org\/providers\/mir-b-ali\" data-vars-ga-call-to-action=\"Mir Ali\" class=\"body-link css-7bauu1 emevuu60\" rel=\"nofollow noopener\">Mir Ali<\/a>, MD, is the medical director of MemorialCare Surgical Weight Loss Center at Orange Coast Medical Center in Fountain Valley, CA. <a href=\"https:\/\/www.vanderbilthealth.com\/doctors\/srivastava-gitanjali\" target=\"_blank\" data-vars-ga-outbound-link=\"https:\/\/www.vanderbilthealth.com\/doctors\/srivastava-gitanjali\" data-vars-ga-ux-element=\"Hyperlink\" data-vars-ga-call-to-action=\"Gitanjali Srivastava\" data-node-id=\"6.4\" class=\"body-link css-7bauu1 emevuu60\" rel=\"nofollow noopener\">Gitanjali Srivastava<\/a>, MD, is co-director of Vanderbilt Weight Loss Clinics.<\/p>\n<p>What is retatrutide?<\/p>\n<p data-journey-content=\"true\" data-node-id=\"8\" class=\"css-6wxqfj emevuu60\">Retatrutide is a triple agonist medication, which means that it works on three different hunger-regulating hormone receptors on the body. This is a GIP, GLP-1, and glucagon triple hormone receptor agonist. <\/p>\n<p data-journey-content=\"true\" data-node-id=\"9\" class=\"css-6wxqfj emevuu60\">To put that into perspective, Ozempic and Wegovy are GLP-1 receptor agonists, while Zepbound and Mounjaro are dual GIP\/GLP-1 receptor agonists. Like these medications, retatrutide is a drug you inject once a week.<\/p>\n<p data-journey-content=\"true\" data-node-id=\"10\" class=\"css-6wxqfj emevuu60\">Retatrutide is not approved yet by the Food and Drug Administration (FDA) for use by the general public. <\/p>\n<p>What did the clinical trial find?<\/p>\n<p data-journey-content=\"true\" data-node-id=\"12\" class=\"css-6wxqfj emevuu60\">The <a href=\"https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lillys-triple-agonist-retatrutide-delivered-weight-loss-average\" target=\"_blank\" data-vars-ga-outbound-link=\"https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lillys-triple-agonist-retatrutide-delivered-weight-loss-average\" data-vars-ga-ux-element=\"Hyperlink\" data-vars-ga-call-to-action=\"clinical trial\" data-node-id=\"12.1\" class=\"body-link css-7bauu1 emevuu60\" rel=\"nofollow noopener\">clinical trial<\/a> followed more than 400 people with obesity and knee osteoarthritis. People who participated in the trial either took a nine milligram or 12 milligram dose of retatrutide once a week for 68 weeks.<\/p>\n<p data-journey-content=\"true\" data-node-id=\"13\" class=\"css-6wxqfj emevuu60\">Overall, retatrutide lowered weight by up to an average of 28.7 percent (or 71.2 pounds). It also reduced pain by up to an average of 4.5 points (or 75.8 percent). <\/p>\n<p data-journey-content=\"true\" data-node-id=\"14\" class=\"css-6wxqfj emevuu60\">For comparison, a separate <a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2416394\" target=\"_blank\" data-saferedirecturl=\"https:\/\/www.google.com\/url?q=https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2416394&amp;source=gmail&amp;ust=1765981262298000&amp;usg=AOvVaw2yhC6N4a1-CE6NdOVKyBnw\" data-vars-ga-outbound-link=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2416394\" data-vars-ga-ux-element=\"Hyperlink\" data-vars-ga-call-to-action=\"study\" data-node-id=\"14.1\" class=\"body-link css-7bauu1 emevuu60\" rel=\"nofollow noopener\">study<\/a> in The New England Journal of Medicine that compared tirzepatide and semaglutide over 72 weeks found people who took tirzepatide lost an average of 50 pounds or about 20.2 percent of their body weight. Participants who took semaglutide lost an average of 33 pounds or 13.7 percent of their body weight.<\/p>\n<p>Related StoriesWhy is this significant?<\/p>\n<p data-journey-content=\"true\" data-node-id=\"17\" class=\"css-6wxqfj emevuu60\">While there are already great weight loss medications on the market that have given plenty of people success, \u201cit doesn\u2019t hurt to have other alternatives,\u201d says <a href=\"https:\/\/www.memorialcare.org\/providers\/mir-b-ali\" target=\"_blank\" data-vars-ga-outbound-link=\"https:\/\/www.memorialcare.org\/providers\/mir-b-ali\" data-vars-ga-ux-element=\"Hyperlink\" data-vars-ga-call-to-action=\"Mir Ali\" data-node-id=\"17.1\" class=\"body-link css-7bauu1 emevuu60\" rel=\"nofollow noopener\">Mir Ali<\/a>, MD, medical director of MemorialCare Surgical Weight Loss Center at Orange Coast Medical Center in Fountain Valley, CA. <\/p>\n<p data-journey-content=\"true\" data-node-id=\"18\" class=\"css-6wxqfj emevuu60\">As for this specific alternative, the weight loss results are \u201cremarkable\u201d so far, says <a href=\"https:\/\/www.vanderbilthealth.com\/doctors\/srivastava-gitanjali\" target=\"_blank\" data-vars-ga-outbound-link=\"https:\/\/www.vanderbilthealth.com\/doctors\/srivastava-gitanjali\" data-vars-ga-ux-element=\"Hyperlink\" data-vars-ga-call-to-action=\"Gitanjali Srivastava\" data-node-id=\"18.1\" class=\"body-link css-7bauu1 emevuu60\" rel=\"nofollow noopener\">Gitanjali Srivastava<\/a>, MD, co-director of Vanderbilt Weight Loss Clinics. The data \u201chighlight retatrutide as a potential breakthrough therapy,\u201d she says. <\/p>\n<p data-journey-content=\"true\" data-node-id=\"19\" class=\"css-6wxqfj emevuu60\">Dr. Srivastava flags the gastrointestinal side effects\u2014like many of these medications, some people had nausea, diarrhea, constipation, and vomiting\u2014but says that the \u201crobust\u201d weight loss makes this an attractive option for people with severe obesity who also have knee arthritis. \u201cIt holds particular promise for those seeking deeper weight loss and broader health gains,\u201d she adds. However, some doctors say lower doses may be considered for people seeking more modest weight loss, too.<br data-node-id=\"19.1\"\/> <\/p>\n<p data-journey-content=\"true\" data-node-id=\"20\" class=\"css-6wxqfj emevuu60\">But Dr. Ali also points out that more research is needed. \u201cWe still need to see a long-term side effect profile,\u201d he says. <\/p>\n<p data-journey-content=\"true\" data-node-id=\"21\" class=\"css-6wxqfj emevuu60\">Also, it&#8217;s worth noting that these medications are still the most effective when they\u2019re used forever, which is tricky from a cost and weight loss maintenance perspective. \u201cIt is common for patients to regain weight when they stop these medications,&#8221; he says. &#8220;If patients don&#8217;t make significant long-term changes to their diet and lifestyle, nothing will change.\u201d <\/p>\n<p><img src=\"https:\/\/www.newsbeep.com\/ca\/wp-content\/uploads\/2025\/12\/1765966336_271_ea27d1a6-ecd9-4da8-b2a7-049a03b4ab93_1528214135.file\" alt=\"Headshot of Korin Miller\" title=\"Headshot of Korin Miller\" width=\"100%\" height=\"100%\" decoding=\"async\" loading=\"lazy\" class=\"css-o0wq4v ev8dhu53\"\/><\/p>\n<p>Korin Miller is a freelance writer specializing in general wellness, sexual health and relationships, and lifestyle trends, with work appearing in Men\u2019s Health, Women\u2019s Health, Self, Glamour, and more. She has a master\u2019s degree from American University, lives by the beach, and hopes to own a teacup pig and taco truck one day.<\/p>\n","protected":false},"excerpt":{"rendered":"Eli Lilly just announced phase 3 clinical trial results for its new medication, retatrutide, and it could become&hellip;\n","protected":false},"author":2,"featured_media":350858,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[33],"tags":[49,48,152437,152434,51520,84,377,106041,13665,152435,152436],"class_list":{"0":"post-350857","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-medication","8":"tag-ca","9":"tag-canada","10":"tag-clinical-trial-results","11":"tag-eli-lilly-drug","12":"tag-glp-1s","13":"tag-health","14":"tag-medication","15":"tag-retatrutide","16":"tag-semaglutide","17":"tag-triple-agonist","18":"tag-triple-agonist-weight-loss-medication"},"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/posts\/350857","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/comments?post=350857"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/posts\/350857\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/media\/350858"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/media?parent=350857"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/categories?post=350857"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/tags?post=350857"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}